论文部分内容阅读
目的探讨氯吡格雷联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法选取重庆市合川区人民医院2016年2—11月收治的急性脑梗死患者96例,随机分为对照组和联合用药组,各48例。对照组患者给予氯吡格雷治疗,联合用药组患者在对照组基础上联合依达拉奉治疗,两组患者均持续治疗2周。比较两组患者的临床疗效,治疗前后超敏C反应蛋白、白介素6(IL-6)、血细胞比容、总胆固醇水平及神经功能缺损评分、SF-36生活质量评分、日常生活活动能力(BI)指数,观察患者不良反应发生情况。结果联合用药组患者治疗总有效率高于对照组(P<0.05)。治疗前,两组患者超敏C反应蛋白、IL-6、血细胞比容、总胆固醇水平比较,差异无统计学意义(P>0.05);治疗后,联合用药组患者超敏C反应蛋白、IL-6、血细胞比容、总胆固醇水平低于对照组(P<0.05)。治疗前,两组患者神经功能缺损评分、SF-36生活质量评分、BI指数比较,差异无统计学意义(P>0.05);治疗后,联合用药组患者神经功能缺损评分低于对照组,SF-36生活质量评分、BI指数高于对照组(P<0.05)。两组患者均未出现严重不良反应。结论采用氯吡格雷联合依达拉奉治疗急性脑梗死的临床疗效确切,可有效改善患者血脂、血液流变学,降低炎性反应,改善神经功能,提高患者的生活质量和自理能力,且用药安全。
Objective To investigate the clinical efficacy and safety of clopidogrel plus edaravone in the treatment of acute cerebral infarction. Methods A total of 96 patients with acute cerebral infarction who were admitted to Hechuan District People’s Hospital of Chongqing from February to November, 2016 were randomly divided into control group and combination group, 48 cases in each group. Patients in the control group were treated with clopidogrel. Patients in the combination group were treated with edaravone on the basis of the control group, and both groups were treated for 2 weeks. The clinical curative effect was compared between the two groups before and after treatment. The levels of high sensitivity C-reactive protein, interleukin 6 (IL-6), hematocrit, total cholesterol and neurological deficit score, SF- ) Index, observation of patients with adverse reactions occurred. Results The total effective rate of treatment in combination group was higher than that in control group (P <0.05). Before treatment, there were no significant differences in the levels of high-sensitivity C-reactive protein, IL-6, hematocrit and total cholesterol between the two groups (P> 0.05). After treatment, the combined use of high-sensitivity C-reactive protein -6, hematocrit and total cholesterol were lower than those in the control group (P <0.05). Before treatment, there was no significant difference in neurological deficit score, SF-36 quality of life score and BI index between the two groups (P> 0.05). After treatment, the score of neurological deficit in the combination group was lower than that in the control group -36 quality of life score, BI index higher than the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusions Clopidogrel combined with edaravone is effective in treating acute cerebral infarction. It can effectively improve the patients ’blood lipids, hemorheology, reduce inflammatory reaction, improve neurological function, improve patients’ quality of life and self-care ability, and take medicine Safety.